Cortexyme to Present at Investor Conferences in June 2021
May 26 2021 - 07:00AM
Business Wire
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal
trial in Alzheimer's disease with topline data expected in the
fourth quarter of 2021 and a growing pipeline of therapeutics for
degenerative diseases, announced that Chris Lowe, the company’s
chief operating officer and chief financial officer, will
participate at the following virtual investor conferences in June
2021:
- Jefferies Healthcare Conference on Wednesday, June 2, 2021, at
2:00 p.m. EDT (11:00 a.m. PDT).
- The JMP Securities Life Sciences Conference on Wednesday, June
16, 2021 at 3:00 p.m. EDT (12:00 p.m. PDT).
A live webcast of the events will be accessible on the Investor
Calendar page under the News & Events heading of Cortexyme’s
investor website at ir.cortexyme.com. The webcasts will be archived
at that location for 90 days.
About Cortexyme
Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage
biopharmaceutical company pioneering upstream therapeutic
approaches designed to improve the lives of patients diagnosed with
Alzheimer’s and other degenerative diseases. The company is
advancing its disease-modifying pivotal GAIN Trial in mild to
moderate Alzheimer's disease with top-line data expected in the
fourth quarter of 2021, in addition to growing a proprietary
pipeline of first-in-class small molecule therapeutics for
Parkinson’s disease, periodontitis, and other diseases with high
unmet clinical need. Cortexyme’s lead program targets a specific,
infectious pathogen called P. gingivalis found in the brain and
other organs and tied to degeneration and inflammation in humans
and animal models. The company’s causation evidence for Alzheimer’s
disease and the mechanism of its novel therapeutic has been
independently replicated and confirmed by multiple laboratories
around the world, as well as published in peer-reviewed scientific
journals. To learn more about Cortexyme, visit www.cortexyme.com or
follow @Cortexyme on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210526005260/en/
Corporate Contact: Stacy Roughan Vice President,
Corporate Communications & Investor Relations Cortexyme, Inc.
IR@cortexyme.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2023 to Mar 2024